Evento

Soluble TNFα blockade overcomes lapatinib resistance and induces an innate immune response in HER2-positive breast cancer

Bruni, SofiaIcon ; Mauro, Florencia LucianaIcon ; de Martino, MaraIcon ; Roldán Deamicis, Agustina; Mercogliano, María FlorenciaIcon ; Elizalde, Patricia VirginiaIcon ; Schillaci, RoxanaIcon
Tipo del evento: Reunión
Nombre del evento: AACR Virtual Annual Meeting 2020
Fecha del evento: 22/06/2020
Institución Organizadora: American Association for Cancer Research;
Título de la revista: Cancer Research
Editorial: American Association for Cancer Research
ISSN: 0008-5472
e-ISSN: 1538-7445
Idioma: Inglés
Clasificación temática:

Resumen

Lapatinib (LAP), a dual EGFR/HER2 tyrosine kinase inhibitor, is used as second-line therapy in women with HER2+ breast cancer (BC), but less than 25% of the patients achieve an objective response. An alternative therapeutic approach is needed to overcome LAP resistance in women with metastatic HER2+ BC, particularly in patients with central nervous system (CNS) metastasis where large biological molecules are not effective.
Palabras clave: TNF , BREAST CANCER , LAPATINIB , HER2
 
Archivos asociados
Thumbnail
 
Tamaño: 72.39Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/255862
URL: https://aacrjournals.org/cancerres/article/80/16_Supplement/1913/641623/Abstract
DOI: http://dx.doi.org/10.1158/1538-7445.AM2020-1913
Colecciones
Eventos(IBYME)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Soluble TNFα blockade overcomes lapatinib resistance and induces an innate immune response in HER2-positive breast cancer; AACR Virtual Annual Meeting 2020; en línea; Estados Unidos; 2020; 1913-1913
Compartir
Altmétricas